# Washington Just Wrote a $2 Billion Check to Quantum — May 21, 2026
*Your daily premarket briefing, brought to you by [SignalDeck.live](https://signaldeck.live).*
The Trump administration is reportedly handing out **$2 billion in grants to nine quantum computing firms in exchange for government equity stakes**, with **IBM confirmed as the largest recipient at $1 billion** to build America’s first purpose-built quantum foundry (a new company called Anderson). This is not a recycled headline or a stale earnings reaction — it’s a fresh, fundamental, sector-wide catalyst that’s lighting up every quantum pure-play in premarket. The cleanest risk-adjusted way to play it isn’t the loudest mover. It’s GlobalFoundries.
## The Top Calls
- **GFS (GlobalFoundries)** · Semiconductors · +12.7% · EP-β 59 — This is today’s “buy the boring one” trade. GFS just launched its SCALE optical co-packaged-optics platform (the first MSA-standard CPO solution), Q2 revenue guide raised to $1.76B, record 29% gross margin, and the company declared its first-ever quarterly dividend. RS 60.8 puts it in emerging-rotation territory — not the top of the leaderboard, but climbing fast. Days-to-cover at 10 is real squeeze fuel hiding under a large-cap stock that nobody is calling a meme play. AI infrastructure rotation is bidding semis whether or not the quantum grant rumor is true, which makes this a two-way win.
- **INFQ (Infleqtion)** · Software - Infrastructure · +20.9% · EP-β 69 — Biggest tape on the day with **23.96x relative volume and 119.8% of average daily volume already done in premarket**. That’s institutional money positioning before the open, not retail froth. The company raised its FY26 revenue guide to $40M+ last week (5/14) and the CEO is presenting at the Canaccord Quantum Symposium today at 2 PM ET. Note the catch: recent SPAC listing means the volume baseline is unstable — the KLAR precedent (5/14 D1 +20%, D2 -7.8%) is a real risk. Size accordingly.
- **RLAY (Relay Therapeutics)** · Biotechnology · +12.0% · EP-β 59 — Day 2 follow-through on Tuesday’s Phase 2 ReInspire zovegalisib data + FDA Breakthrough Therapy Designation. This is R10.1 firing on Day 2 instead of the canonical Day 4-6 — same pattern we saw on HIMX a week ago. The squeeze setup is real: 19% short float, 10.8 days-to-cover, volume score qualified. But the stock’s relative strength is still in the bottom 16th percentile, which means this only works if the first-hour gap holds. If it fades from the open, the DSGN-on-Monday script (-25% distribution day on positive Phase 1/2 clinical data) is what gets you. **Confirmation rule: green Change-from-Open at the 10:30 ET mark or stand down.**
- **RGTI (Rigetti) and QBTS (D-Wave)** · Computer Hardware · +12.7% / +14.3% · EP-β 52 each — The quantum pure-plays that the market thinks will be on the $2B grant list. Both have squeeze setups (15-16% short float + confirmed volume). RGTI is the cleaner story (Q1 revenue +193% YoY on the recent print, $100M UK 1000-qubit investment plan announced). QBTS is messier — Q1 revenue MISSED at -81% YoY, but the bookings story is the loudest in the sector: $33.4M Q1 bookings up 2000% YoY including a $20M Florida Atlantic University system sale. If those bookings convert to revenue in Q2-Q3, this re-rates. If they don’t, it fades.
> **Risk callout:** Today’s catalyst is a *reported* government grant per WSJ, not a Treasury press release. If the formal announcement names different recipients than the market is pricing in (or pushes the timing back), all the pure-plays except IBM revert to their fundamentals — which for QBTS means a stock priced on $33M of bookings against $2.9M of actual quarterly revenue. Position size accordingly.
## The Quiet Beats
- **ELF (e.l.f. Beauty)** · Household & Personal Products · +8.6% · EP-β 60 — Q4 FY26 reported AMC last night: 29th consecutive quarter of net sales growth, FY26 net sales +25%, +115 basis points of US market share gain (the biggest grab among nearly 1,000 cosmetics brands tracked by Nielsen). The market punished this stock relentlessly into the print — RS in the 7th percentile, near a 52-week low — so the +8.6% gap is partly oversold mechanics. FY27 guide was *maintained* at +12-14% sales growth, which is a deceleration from +25% but not a disaster. Bottom-decile RS + 12.9% short float + double-digit beats on both top and bottom = textbook oversold-rebound vehicle. Two-week compounder candidate if it holds the gap.
- **IBM (honorable mention)** · IT Services · +5.3% — Gap-gate failed (under 8%) so it doesn’t get a formal EP-β tag, but **this is the safest exposure to today’s theme**. $1 billion direct government grant confirmed, mega-cap stability, no SPAC-vol unpredictability, no biotech binary risk. A 4.76x rVol on a mega-cap is unusual. If you want to play the quantum theme but can’t stomach the volatility of the pure-plays, IBM is the anchor position. Pair it with INFQ or RGTI as the upside satellite.
> **Pattern callout:** When the market gets a real fundamental catalyst (this one is real, not a meme), the pure-plays gap hardest but fade easiest because the rally is news-driven, not earnings-driven. The boring large-caps that catch sympathy bids tend to hold the move better.
## Yesterday’s Lessons
- **AGYS** — 5/19 Pick #1 at EP-β 86. D1 RS jumped from 70.6 → 95.0 (elite). The “blowout-and-raise from a profitable SaaS at mid-cap scale + KPI-library independent confirmation” framework worked exactly as designed. KPI verdict ✅ BLOWOUT was the right call.
- **CMBT** — 5/19 Pick #4. RS jumped 83.2 → 97.1 at D1. Multi-vector setup (earnings beat + hot Energy sector + elite RS + KPI library coverage) delivered the “slow-grind multi-day compounder” thesis on schedule.
- **DSGN** — 5/18 Pick #1 at EP-β 74 (best risk-adjusted by my own framing). Down -25% on D1 with Change-from-Open ~-33%. **R14.1 distribution-day mechanics apply to clinical catalysts, not just earnings.** A positive Phase 1/2 readout still got sold by R14.1 mechanics when sample size was small and pre-print run-up consumed the upside. Rule promoted to CONFIRMED today (instance #2 with RLAY’s first-hour gap-hold requirement built into today’s call).
- **TE** — 5/18 Pick #2. Down -3.4% D1, Change-from-Open -7.65%. Delayed-catalyst (5-day-late +21% gap with no fresh confirmer) faded exactly as the counter-thesis predicted. **R14.x.2 promoted from caveat to hard scoring rule: reject delayed-catalyst patterns without a fresh news confirmer.** That rule kept us from chasing today’s stale quantum earnings prints (QBTS 5/13, RGTI 5/11, INFQ 5/14) — those would have been disqualified if not for today’s fresh $2B grant catalyst rewriting the thesis.
## The Read
**Best risk-adjusted trade today:** **GFS** — large-cap stability + real product news (SCALE CPO MSA) + Q2 guide raised + DTC 10 hidden squeeze fuel + AI infra rotation already underway. EP-β 59 understates because the earnings component is stale, but the structural setup is the cleanest on the tape.
**Highest-upside speculative trade:** **INFQ** — 23.96x rVol confirms institutional positioning, EP-β 69, raised guide on a credible business. Size for the SPAC-vol caveat. If it holds the open, the conviction is real.
**Best two-week compounding trade:** **GFS** (semi rotation + dividend initiation has tail) or **ELF** (oversold rebound on real Q4 beat). Both are positioned for analyst-model recalibration over 2-3 weeks rather than same-day rip.
**Pair trade for the theme:** **IBM** anchor + one of **INFQ/RGTI/QBTS** satellite. IBM absorbs portfolio risk while the pure-plays carry the upside.
**Don’t chase:** **QBTS** — story is bookings, not revenue. Bookings need to convert. Market patience has limits.
**Hard skip:** **QUBT** — governance blacklist (validated Iceberg/Capybara short reports + active class-action). The 30% short float + 7.4x rVol setup is real squeeze fuel. Doesn’t matter. Numbers from this company can’t be trusted.
**Lesson banked:** R14.1 distribution-day mechanics now CONFIRMED across earnings catalysts AND clinical catalysts. Today’s RLAY call has a mandatory first-hour gap-hold confirmation built in — not optional.
---
**Not financial advice.** This is independent market analysis and momentum research, not a recommendation to buy or sell anything. Markets are volatile, individual securities can lose 100% of their value, and past performance does not predict future results. Do your own due diligence, size positions you can afford to lose, and consult a licensed financial advisor before making investment decisions. Your money, your risk, your call.